Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 3/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14160113 | 0.89 | SCN1A (0.51) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL5411041 | 0.88 | SCN1A (0.50) | SCN1ASCN2ASCN3ALMNAHTT | |
| Nitric Acid SCHEMBL9874458 | 0.87 | GSR (0.47) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL4667514 | 0.87 | SCN1A (0.53) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL4669215 | 0.86 | ACP3 (0.50) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL4667564 | 0.85 | SCN1A (0.65) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL4669156 | 0.85 | SCN1A (0.52) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL4667558 | 0.84 | FFAR1 (0.48) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL28352196 | 0.84 | SCN1A (0.50) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL7120235 | 0.82 | ALDH1A1 (0.46) | SCN1ASCN2ASCN3ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117603063-A | Synthesis method of N, N-dimethylaminoethyl benzhydryl ether | 浙江大学 | 2024-02-27 | — | — | CN | disclosed |
| US-10919909-B2 | Photoinitiated reactions | LINTFIELD LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20190211031-A1 | PHOTOINITIATED REACTIONS | LINTFIELD LIMITED (GB) | 2019-07-11 | — | — | US | disclosed |
| US-10221193-B2 | Photoinitiated reactions | Lintfiled Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20130105297-A1 | PHOTOINITIATED REACTIONS | LINTFIELD LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130105297-A1 | PHOTOINITIATED REACTIONS | LINTFIELD LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| EP-1043931-B1 | BIOSTATIC COATINGS FOR THE REDUCTION AND PREVENTION OF BACTERIAL ADHESION | HYDROMER INC (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1930308-A1 | Pharmaceutical agents for the treatment of cerebral amyloidosis | NYMOX CORPORATION (CA) | 2008-06-11 | — | — | EP | disclosed |
| EP-1930308-A1 | Pharmaceutical agents for the treatment of cerebral amyloidosis | NYMOX CORPORATION (CA) | 2008-06-11 | — | — | EP | disclosed |
| EP-0983222-B1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORP (CA) | 2007-11-28 | — | — | EP | disclosed |
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-6323235-B1 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS AND ENZYME INHIBITORS | OHTAKE ATSUSHI (JP) | 2001-11-27 | — | — | US | disclosed |
| US-6130221-A | ALZHEIMERS | NYMOX CORPORATION (CA) | 2000-10-10 | — | — | US | disclosed |
| US-6043264-A | A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA | TORAY INDUSTRIES, INC. (JP) | 2000-03-28 | — | — | US | disclosed |
| EP-0983222-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORPORATION (CA) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052898-A9 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORP (CA) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998052898-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORPORATION (CA) | 1998-11-26 | — | — | WO | disclosed |
| EP-0751126-A1 | BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME | TORAY INDUSTRIES, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
| EP-0613880-A1 | Agent and method for the immunological determination of Diphenhydramine and its metabolites | MERCK PATENT GmbH (DE) | 1994-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919909-B2 | Photoinitiated reactions | KMO, DECR1, PPOX | SCN1A 4353/4885SCN2A 4525/4885SCN3A 3942/4885 |
| US-20130105297-A1 | PHOTOINITIATED REACTIONS | KMO, DECR1, DDT | SCN1A 4327/4885SCN2A 4507/4885SCN3A 3872/4885 |
| US-10221193-B2 | Photoinitiated reactions | KMO, DECR1, DDT | SCN1A 4327/4885SCN2A 4507/4885SCN3A 3872/4885 |
| US-20190211031-A1 | PHOTOINITIATED REACTIONS | DOHH, PAH, DBH | SCN1A 4438/4885SCN2A 4454/4885SCN3A 4073/4885 |
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | SCN1A 29/4885SCN2A 30/4885SCN3A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.